Abstracts

Implications of Poor CD4 Recovery During HIV Suppressive ART in Sub-Saharan Africa

Background: Achieving undetectable plasma viral load (VL) on antiretroviral therapy (ART) is not always accompanied by the recovery of CD4 count. This study evaluates determinants, clinical outcomes and time trends of poor CD4 recovery in patients receiving suppressive ART in the Pan-African Studies to Evaluate Resistance Monitoring (PASER-M) cohort. Methods: In 2585 patients with pre-ART…

Better CD4/CD8 Restoration in First-Line HIV-Infected CMV-Seronegative Patients

Background: CMV-infection is highly prevalent among HIV-infected patients. We investigated its impact on immune reconstitution in HIV-infected patients receiving their first cART. Methods: From the French multicenter Dat’AIDS cohort, we selected patients who initiated a first cART between 2002 and 2009, maintained an undetectable plasma viral load (pVL) for at least 12 months with the…

CD4 Response in Treatment-Naïve HIV-2–Infected Patients: The IeDEA West Africa Cohort

Background: Response to antiretroviral therapy (ART) among individuals infected with human immunodeficiency virus type 2 (HIV-2) is poorly understood. We compared the immunological response among patients treated with three nucleoside reverse transcriptase inhibitors (NRTIs) and with protease inhibitor (PI) based regimens. Methods: This prospective cohort study enrolled HIV-2-infected patients within the International epidemiological Database to…

Mortality and Retention After 12 Months in a Cohort of Patients Initiated With the New WHO Recommendations in Uganda

Background: The 2013 WHO guidelines recommend to start ART in all individuals with CD count 500 cells/mm3 or less regardless clinical stage. Evidence for clinical benefit of initiation between 350-500 cells is limited and relies mainly in observational studies from high income countries. Concerns about high risk of defaulting in those patients have also been…

Impact of Specific Antiretroviral Drugs on Non-AIDS Mortality; the D:A:D Study

Background: In previous studies, protease inhibitors (PIs) have been associated with an increased risk of death and non-AIDS events, such as cardiovascular events and non-AIDS cancers. We investigated whether specific PIs and non-nucleoside transcriptase inhibitors (NNRTIs) are associated with increased non-AIDS mortality. Methods: D:A:D study participants were followed from study enrolment until earliest of death,…

HIV-Related Causes of Death in the Era of Antiretroviral Therapy: Analysis of Verbal Autopsy Data

Background: Mortality rates remain higher in HIV positive than HIV negative individuals despite the introduction of antiretroviral therapy (ART). Understanding the causes of death in HIV positive individuals, and how these have altered with ART treatment, will help direct interventions to prevent these deaths. Since causes of death are not medically certified in sub-Saharan Africa…

Facility-Level Factors Associated With Mortality of Patients on ART: A Retrospective Cohort Study in Kenya, 2007-2012

Background: While the individual-level benefits of antiretroviral therapy (ART) are well established, much remains to be understood about the population-level impacts of ART scale-up in Kenya and other Sub-Saharan African countries. Most knowledge of mortality levels and determinants comes from relatively small or unrepresentative study sites that may not accurately reflect full national programs. In…